Pimozide-d4

• UNSPSC Description:

  Pimozide-d4 is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].

• Target Antigen:

  Adrenergic Receptor; Dopamine Receptor; STAT

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;JAK/STAT Signaling;Neuronal Signaling;Stem Cell/Wnt

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Endocrinology; Neurological Disease

• Purity:

  98.0

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=C([2H])C([2H])=C(F)C([2H])=C5[2H])CC3

• Molecular Weight:

  465.57

• References & Citations:

  [1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256(2):141-7.|[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9(8):3853-3866. eCollection 2017.|[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12): 3421-3429.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 4

• CAS Number:

  1803193-57-8